{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-23-000025","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.106425+00:00","generated_at":"2026-06-19T08:50:47.754006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth","bullets":["Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).","Life Science segment $359.7M (+10.1%); Clinical Diagnostics $369.6M (-8.7%).","GAAP net income $827.7M ($27.78 diluted) from Sartorius fair value; non-GAAP net income $98.5M ($3.31).","Full-year 2022 net sales $2,802.2M (-4.1%); non-GAAP EPS $14.42 vs $15.94 prior year.","FY2023 outlook: non-GAAP currency-neutral revenue growth ~6-7%, non-GAAP operating margin ~19.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-23-000025","json":"https://secwatch.observer/filing/0000012208-23-000025.json","markdown":"https://secwatch.observer/filing/0000012208-23-000025.md","text":"https://secwatch.observer/filing/0000012208-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/bio-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:50:47.754006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"720fc20d53d7195427622fe48b91248c312fd941","claim":"BIO-RAD LABORATORIES, INC. reported Fourth-quarter 2022 results: revenue $730.3 million, net income $827.7 million, EPS $27.78 per share, on a diluted basis.","evidence_excerpt":"Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth-quarter 2022"},{"label":"Revenue","value":"$730.3 million"},{"label":"Net income","value":"$827.7 million"},{"label":"EPS","value":"$27.78 per share, on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ea44441e95aa2321246a97738583bbc999cd3093","claim":"BIO-RAD LABORATORIES, INC. reported the full year ended December 31, 2022 results: revenue $2,802.2 million.","evidence_excerpt":"On a reported basis, net sales for the full year 2022 decreased 4.1 percent to $2,802.2 million compared to $2,922.5 million for the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$2,802.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fed8c848605b0ec2392dd633f766f08b12cb435c","claim":"BIO-RAD LABORATORIES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}